Search
Cefacetrile
go.drugbank.com/drugs/DB01414InvestigationalVet approvedA derivative of 7-aminocephalosporanic acid.
Tonapofylline
go.drugbank.com/drugs/DB12569InvestigationalTonapofylline has been used in trials studying the treatment of Heart Failure, Renal Insufficiency, and Congestive Heart Failure.
Gantenerumab
go.drugbank.com/drugs/DB12034InvestigationalAs the classical view of AD pathology posits that Aβ accumulation triggers tau hyperphosphorylation and aggregation to form NFTs and cause neurodegeneration, large efforts have gone into developing treatments
Epcoritamab
go.drugbank.com/drugs/DB16672ApprovedInvestigational[L46516] It is administered subcutaneously and is currently being evaluated as a monotherapy and in combination for the treatment of a variety of hematologic malignancies.
Roxadustat
go.drugbank.com/drugs/DB04847ApprovedInvestigationalRoxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease. It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transc...
DFV890
go.drugbank.com/drugs/DB16461InvestigationalDFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic knee osteoarthritis), NCT0...
Olmutinib
go.drugbank.com/drugs/DB13164InvestigationalOlmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer. It is available under the brand name Olita made by Hanmi Pharmaceuticals . Olmutinib wa...
SAR443122
go.drugbank.com/drugs/DB16492InvestigationalSAR443122, was investigated in several clinical trials to evaluate its safety and efficacy. NCT04469621 was studied in severe COVID-19 patients, while NCT05588843 is currently recruiting participants with ulcerative colitis. Additionally...
AN0128
go.drugbank.com/drugs/DB05054InvestigationalAN0128 is a good candidate for a topical antibiotic and is currently being developed by Anacor as a novel therapeutic for acne and atopic dermatitis.